Gotham Asset Management LLC Boosts Stake in Zimmer Biomet Holdings, Inc. (ZBH)

Gotham Asset Management LLC boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 387.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 164,266 shares of the medical equipment provider’s stock after buying an additional 130,533 shares during the period. Gotham Asset Management LLC owned about 0.08% of Zimmer Biomet Holdings worth $20,059,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of ZBH. Alpha Windward LLC raised its stake in shares of Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock worth $202,000 after buying an additional 18 shares in the last quarter. Sandy Spring Bank raised its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares in the last quarter. Cleararc Capital Inc. raised its stake in shares of Zimmer Biomet Holdings by 0.5% in the first quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock worth $598,000 after buying an additional 25 shares in the last quarter. Finally, Enterprise Financial Services Corp raised its stake in shares of Zimmer Biomet Holdings by 1.0% in the first quarter. Enterprise Financial Services Corp now owns 2,637 shares of the medical equipment provider’s stock worth $322,000 after buying an additional 27 shares in the last quarter. Institutional investors and hedge funds own 84.17% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) opened at 126.49 on Wednesday. The firm’s 50-day moving average price is $123.43 and its 200-day moving average price is $117.75. The company has a market capitalization of $25.51 billion, a price-to-earnings ratio of 51.78 and a beta of 1.21. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.02. The company had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.96 billion. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. Zimmer Biomet Holdings’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.00 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.54 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 23rd will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.76%. The ex-dividend date is Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 39.67%.

TRADEMARK VIOLATION NOTICE: “Gotham Asset Management LLC Boosts Stake in Zimmer Biomet Holdings, Inc. (ZBH)” was published by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.themarketsdaily.com/2017/07/12/gotham-asset-management-llc-boosts-stake-in-zimmer-biomet-holdings-inc-zbh.html.

A number of brokerages recently weighed in on ZBH. BMO Capital Markets restated a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a research report on Tuesday. Guggenheim upgraded Zimmer Biomet Holdings from a “neutral” rating to a “buy” rating in a research report on Wednesday. Citigroup Inc. upped their price target on Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, June 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $148.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, June 30th. Finally, Royal Bank Of Canada upped their price target on Zimmer Biomet Holdings from $133.00 to $140.00 and gave the company an “outperform” rating in a research report on Wednesday, June 21st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet Holdings presently has a consensus rating of “Buy” and a consensus target price of $137.69.

In related news, insider David C. Dvorak sold 87,331 shares of the company’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $116.47, for a total value of $10,171,441.57. Following the completion of the transaction, the insider now owns 381,886 shares of the company’s stock, valued at approximately $44,478,262.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. Insiders sold a total of 111,262 shares of company stock valued at $13,103,927 in the last ninety days. 1.07% of the stock is currently owned by insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply